28 search results for Pancreatic Adenocarcinoma
Guidelines for Patients
Ovarian Cancer Version: 2024 Pancreatic, Adenocarcinoma Version: 2024 Small Cell Lung, Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancers
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patientsHarmonized Guidelines
Version 2.2023 Pancreatic Adenocarcinoma Version 2.2022 Pediatric Acute
https://www.nccn.org/global/what-we-do/harmonized-guidelinesTreatment by Cancer Type
Pancreatic Cancer Version: 2023, Small Bowel Adenocarcinoma Version: 2024, , Pancreatic, and Prostate Cancers Version: 2025
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/treatment-by-cancer-typeDetection, Prevention, and Risk Reduction
Pancreatic Cancer Version: 2023, Small Bowel Adenocarcinoma Version: 2024, , Pancreatic, and Prostate Cancers Version: 2025
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/detection-prevention-and-risk-reductionSupportive Care
Pancreatic Cancer Version: 2023, Small Bowel Adenocarcinoma Version: 2024, , Pancreatic, and Prostate Cancers Version: 2025
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/supportive-careSpecific Populations
Pancreatic Cancer Version: 2023, Small Bowel Adenocarcinoma Version: 2024, , Pancreatic, and Prostate Cancers Version: 2025
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/specific-populationsSubmission Request History
, Inc. on 06/10/2020 Pembrolizumab for Small Bowel Adenocarcinoma Submitted by Merck & Co, Mutational Burden (TMB) for Small Bowel Adenocarcinoma Submitted by Foundation Medicine, Inc, Adenocarcinoma Submitted by GlaxoSmithKline on 08/17/2021 Contrast-Enhanced Ultrasound, on 04/11/2022 Nivolumab + ipilimumab for Small Bowel Adenocarcinoma Submitted by Bristol, Adenocarcinoma Submitted by Eli Lilly and Company on 09/21/2022 Adagrasib monotherapy and adagrasib
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-historyAnnual Report
Polymerase as Maintenance Treatment for Advanced TP53 Mutant Pancreatic Ductal Adenocarcinoma Chengwei, Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate
https://www.nccn.org/docs/default-source/about/annual-report.pdf?sfvrsn=8411082_40